Search Results 111-120 of 23169 for B cell lymphomas

  1. Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma - Mayo Clinic

    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma · Overview · Participation eligibility · Participating Mayo Clinic ...

  2. Recent findings and future directions in non-Hodgkin's lymphoma therapy - Mayo Clinic

    Ansell's lymphoma research program, which focuses on the TME and B cell cancer biology, has produced over 450 journal articles, including the 2021 paper in JCO ...

  3. Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma - Mayo Clinic

    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Print details. Share; Facebook ...

  4. Escalating Dose Study in Subjects with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia - Mayo Clinic

    Escalating Dose Study in Subjects with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.

  5. Cutaneous T-Cell Lymphoma Clinical Trials - Mayo Clinic Research

    The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.

  6. Publications - Javier L. Munoz, M.D., M.B.A. - Mayo Clinic

    ... B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 (10):753-759 Epub 2022 May 23. View PubMed; Munoz JL ...

  7. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    ... B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL). Participation eligibility.

  8. GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 - Mayo Clinic

    Clinical Trials · GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 · More about research at Mayo ...

  9. Follow-up Letters for Subjects in the IRB# 13-001285 "Mayo Clinic Experience with Subjects Diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)" Study

    Follow-up Letters for Subjects in the IRB# 13-001285 "Mayo Clinic Experience with Subjects Diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)" Study. Print ...

  10. Publications - Rebecca L. King, M.D. - Mayo Clinic

    ... B-Cell Lymphoma Subtype Defined by the Cell of Origin. ... Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young ...